Thoracic Cancer (Nov 2023)

Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy

  • Yi‐Chun Hua,
  • De‐Zhi Gao,
  • Kuan‐Yu Wang,
  • Xiao‐Sheng Ding,
  • Wei‐Ran Xu,
  • Yu‐Bin Li,
  • Wei‐Wei Shi,
  • Shi‐Bin Sun,
  • Xiao‐Yan Li

DOI
https://doi.org/10.1111/1759-7714.15106
Journal volume & issue
Vol. 14, no. 31
pp. 3133 – 3139

Abstract

Read online

Abstract Background The aim of this study was to investigate the efficacy of bevacizumab (Bev) in reducing peritumoral brain edema (PTBE) after stereotactic radiotherapy (SRT) for lung cancer brain metastases. Methods A retrospective analysis was conducted on 44 patients with lung cancer brain metastases (70 lesions) who were admitted to our oncology and Gamma Knife center from January 2020 to May 2022. All patients received intracranial SRT and had PTBE. Based on treatment with Bev, patients were categorized as SRT + Bev and SRT groups. Follow‐up head magnetic resonance imaging was performed to calculate PTBE and tumor volume changes. The edema index (EI) was used to assess the severity of PTBE. Additionally, the extent of tumor reduction and intracranial progression‐free survival (PFS) were compared between the two groups. Results The SRT + Bev group showed a statistically significant difference in EI values before and after radiotherapy (p = 0.0115), with lower values observed after treatment, but there was no difference in the SRT group (p = 0.4008). There was a difference in the distribution of EI grades in the SRT + Bev group (p = 0.0186), with an increased proportion of patients at grades 1–2 after radiotherapy, while there was no difference in the SRT group (p > 0.9999). Both groups demonstrated a significant reduction in tumor volume after radiotherapy (p < 0.05), but there was no difference in tumor volume changes between the two groups (p = 0.4089). There was no difference in intracranial PFS between the two groups (p = 0.1541). Conclusion Bevacizumab significantly reduces the severity of PTBE after radiotherapy for lung cancer. However, its impact on tumor volume reduction and intracranial PFS does not reach statistical significance.

Keywords